• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[影响泌尿道的药物不良反应——维滕泌尿道不良反应评分]

[Adverse drug reaction affecting the urinary tract - the Witten urinary tract adverse reaction score].

作者信息

Wiedemann Andreas, Dündar Vedat, Heese Melanie, Leufgens Thomas, Wirz Stefan, Brauckmann Robin, Heppner Hans-Jürgen

机构信息

Urologische Abteilung, Evangelisches Krankenhaus Witten.

Lehrstuhl für Geriatrie, Universität Witten/Herdecke.

出版信息

Aktuelle Urol. 2021 Sep;52(5):481-489. doi: 10.1055/a-1352-9370. Epub 2021 May 31.

DOI:10.1055/a-1352-9370
PMID:34058770
Abstract

The urinary tract is the site of many adverse drug reactions, including the formation of residual urine, urinary retention, pollakisuria, polyuria, nycturia, detrusor stimulation, detrusor inhibition, haematuria, dysuria and other symptoms. Nevertheless, there is no general overview or evaluation of the substances that can trigger these adverse drug reactions. The available lists of "potential inadequate medication" either focus on a pharmacological group of adverse reactions ("anticholinergic burden score"), a group of drugs for a specific indication (LUTS-Forta) or on a selected group of patients (PRISKUS List, Beers List).The following interdisciplinary project has been processed by the group for urogeriatrics in the University of Witten/Herdecke and is intended to fill this gap. We have identified substances which can in principle trigger adverse reactions in the urinary tract - according to a variety of databases. We also categorise the available literature (case reports, case series, RCT, meta-analysis) and present a structured analysis of the risk by 33 experts. This results in a list of 235 substances that can lead to various different adverse reactions of the urinary tract. This list includes a "theoretical" score from the reports in the databases or the corresponding literature, a "practical" score based on an expert evaluation of clinical reality and a cumulative score, classified in accordance with the Rote Liste".It is now possible to classify the extent to which newly prescribed drugs may pose a risk of adverse reactions in different patients. Conversely, this may also help to clarify whether a functional disorder of the urinary tract is fully or partially linked to treatment with a specific drug. We plan to develop an app to assess adverse drug reactions in the urinary tract.

摘要

尿路是许多药物不良反应的发生部位,包括残余尿形成、尿潴留、尿频、多尿、夜尿、逼尿肌刺激、逼尿肌抑制、血尿、排尿困难等症状。然而,对于能够引发这些药物不良反应的物质,目前尚无全面的概述或评估。现有的“潜在不适当用药”清单要么侧重于某一药理学不良反应组(“抗胆碱能负担评分”)、某一特定适应症的一组药物(LUTS - Forta),要么侧重于某一选定的患者群体(PRISKUS清单、Beers清单)。维滕/黑尔德克大学的老年泌尿病学小组开展了以下跨学科项目,旨在填补这一空白。我们根据各种数据库确定了原则上可在尿路引发不良反应的物质。我们还对现有文献(病例报告、病例系列、随机对照试验、荟萃分析)进行了分类,并由33位专家对风险进行了结构化分析。这得出了一份包含235种物质的清单,这些物质可导致尿路的各种不同不良反应。该清单包括来自数据库报告或相应文献的“理论”评分、基于专家对临床实际情况评估的“实际”评分以及根据《德国药品索引》分类的累积评分。现在可以对新开具的药物在不同患者中引发不良反应的风险程度进行分类。反之,这也有助于明确尿路功能障碍是否完全或部分与特定药物治疗有关。我们计划开发一款应用程序来评估尿路中的药物不良反应。

相似文献

1
[Adverse drug reaction affecting the urinary tract - the Witten urinary tract adverse reaction score].[影响泌尿道的药物不良反应——维滕泌尿道不良反应评分]
Aktuelle Urol. 2021 Sep;52(5):481-489. doi: 10.1055/a-1352-9370. Epub 2021 May 31.
2
EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.EAU 指南:非神经原性男性下尿路症状包括良性前列腺增生的评估。
Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19.
3
Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.一项为期12周的前瞻性、开放标签、随机试验,旨在研究抗胆碱能药物或抗利尿药物作为α受体阻滞剂附加疗法对下尿路症状的影响。
Clin Interv Aging. 2014 Jul 10;9:1021-30. doi: 10.2147/CIA.S64194. eCollection 2014.
4
Lower Urinary Tract Symptoms: What's New in Medical Treatment?下尿路症状:医学治疗的新进展?
Eur Urol Focus. 2018 Jan;4(1):17-24. doi: 10.1016/j.euf.2018.04.005. Epub 2018 Apr 14.
5
The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.下尿路症状疑似良性前列腺增生患者夜尿症的评估以及夜尿症药物或安慰剂治疗后的疗效分析:一项随机安慰剂对照研究。
BMC Urol. 2018 Dec 13;18(1):115. doi: 10.1186/s12894-018-0426-4.
6
Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia.吸入性抗胆碱能药物与下尿路症状或良性前列腺增生男性的急性尿潴留。
Ann Pharmacother. 2012 Sep;46(9):1245-9. doi: 10.1345/aph.1R282. Epub 2012 Jul 31.
7
[Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : A short-term clinical observation].宁米泰胶囊缓解良性前列腺增生患者下尿路症状:一项短期临床观察
Zhonghua Nan Ke Xue. 2018;24(1):72-77.
8
Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).去氨加压素对提示良性前列腺增生的下尿路症状(LUTS/BPH)男性患者夜间多尿所致夜尿症的影响。
World J Urol. 2014 Oct;32(5):1163-70. doi: 10.1007/s00345-014-1381-7. Epub 2014 Aug 19.
9
Evaluating the Efficacy and Safety of Silodosin on Nocturia in Patients With Benign Prostatic Hyperplasia: A Multicenter, Prospective, Open-label, Single-arm, Phase IV Trial.评估西洛多辛对良性前列腺增生患者夜尿症的疗效和安全性:一项多中心、前瞻性、开放标签、单臂、IV期试验。
Urology. 2018 Nov;121:153-157. doi: 10.1016/j.urology.2018.07.008. Epub 2018 Aug 9.
10
Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.加压素联合治疗在接受 α 受体阻滞剂治疗下尿路症状的男性患者中难治性夜间尿频。
J Urol. 2013 Jul;190(1):180-6. doi: 10.1016/j.juro.2013.01.057. Epub 2013 Jan 25.

引用本文的文献

1
[Urine retention-From the symptom to the structure].[尿潴留——从症状到结构]
Urologie. 2023 Nov;62(11):1223-1233. doi: 10.1007/s00120-023-02216-z.
2
[Polypharmacy and medication review in the context of prehabilitation].[术前康复背景下的多重用药与用药评估]
Urologie. 2023 Oct;62(10):1025-1033. doi: 10.1007/s00120-023-02174-6. Epub 2023 Sep 8.
3
[Urine retention-From the symptom to the structure].[尿潴留——从症状到结构]
Z Gerontol Geriatr. 2023 Mar;56(2):153-163. doi: 10.1007/s00391-022-02133-4. Epub 2023 Feb 15.